Loading...
Loading...
RZLT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 15.9M |
| Operating I/L | -15.9M |
| Other Income/Expense | -0.0M |
| Interest Income | 1.4M |
| Pretax | -14.5M |
| Income Tax Expense | -1.4M |
| Net Income/Loss | -14.5M |
Rezolute, Inc. is a clinical stage biopharmaceutical company focused on developing transformative therapies for metabolic diseases associated with chronic glucose imbalance. The company's lead product candidate, RZ358, is a human monoclonal antibody in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is developing RZ402, a selective and potent plasma kallikrein inhibitor in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.
